AR067357A1 - Piperidonas sustituidas como inductores hsp - Google Patents

Piperidonas sustituidas como inductores hsp

Info

Publication number
AR067357A1
AR067357A1 ARP080102806A ARP080102806A AR067357A1 AR 067357 A1 AR067357 A1 AR 067357A1 AR P080102806 A ARP080102806 A AR P080102806A AR P080102806 A ARP080102806 A AR P080102806A AR 067357 A1 AR067357 A1 AR 067357A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
amino
Prior art date
Application number
ARP080102806A
Other languages
English (en)
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of AR067357A1 publication Critical patent/AR067357A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)

Abstract

Los compuestos de la presente son inductores de HSP y en virtud de este efecto, son utiles para el tratamiento de diversas enfermedades que acompanan al estrés patologico. También se refiere al uso de los compuestos antes mencionados para la preparacion de un medicamento para utilizar como producto farmacéutico. Reivindicacion 1. Un compuesto de formula (1) o (2), o sus sales aceptables para uso farmacéutico y sus hidratos, solvatos, estereoisomeros, conformeros, tautomeros, polimorfos y sus profármacos, donde, R1 se selecciona entre lo siguiente sustituido o no sustituido: a) Arilo monocíclico o bicíclico de cinco a doce miembros, b) heteroarilo monocíclico o bicíclico de cinco a doce miembros donde, contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno y azufre, o c), heterociclilo monocíclico o bicíclico de cuatro a doce miembros donde, contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno y azufre; Dicho arilo, heteroarilo, heterociclilo cuando están sustituidos, está sustituido con uno a cuatro sustituyentes de R8, preferentemente uno a tres sustituyentes de R8, más preferentemente uno a dos sustituyentes de R8, donde R8 se selecciona independientemente del grupo formado por: halogeno, -OH, -SH, alquilo C1-8, nitro, amino, ciano, -N(R9)C(O)(alquilo C1-8), -N(R9)C(O)(arilo), -N(R9)C(O)(heteroarilo), -N(R9)C(O)(heterociclilo), -N(R9)SO2(alquilo C1-8), -N(R9)SO2(arilo), -N(R9)SO2(heteroarilo), -N(R9)SO2(heterociclilo), -N(R9)SO2CF3, -COOH, -C(O)N(R9)(R9), -C(O)N(R9)(arilo), -C(O)N(R9)(heteroarilo), -C(O)N(R9)(heterociclilo), -SO2N(R9)(R9), -SO2N(R9)(arilo), -SO2N(R9)(heteroarilo), -SO2N(R9)(heterociclilo), -C(O)O-(alquilo C1-8), -C(O)O-arilo, -C(O)O-heteroarilo, -C(O)O-heterociclilo, -N(R9)C(O)O-(alquilo C1-8), -N(R9)C(O)O-arilo, -N(R9)C(O)O-heteroarilo, -N(R9)C(O)O-heterociclilo, -CF3, -C(O)CF3, -SO2CF3, -(alquilo C1-8)m-O-(alquilo C1-8), -(alquilo C1-8)m-O-(arilo), -(alquilo C1-8)m-O-(heteroarilo), -(alquilo C1-8)m-O-(heterociclilo), -(alquilo C1-8)m-N(R9)(alquilo C1-8), -(alquilo C1-8)m-N(R9)(arilo), -(alquilo C1-8)m-N(R9)(heteroarilo), -(alquilo C1-8)m-N(R9)(heterociclilo), -(alquilo C1-8)m-C(O)(alquilo C1-8), -(alquilo C1-8)-C(O)(arilo), -(alquilo C1-8)m-C(O)(heteroarilo), -(alquilo C1-8)m-C(O)(heterociclilo), - C(O)(alquilo C1-8)-arilo, -C(O)(alquilo C1-8)-heteroarilo, -C(O)(alquilo C1-8)-heterociclilo, -(alquilo C1-8)m-S(O)(alquilo C1-8), -(alquilo C1-8)mS(O)(arilo), -(alquilo C1-8)m-S(O)(heteroarilo), -(alquilo C1-8)-S(O)(heterociclilo), -(alquilo C1-8)m-S(O)2(alquilo C1-8), -(alquilo C1-8)m-S(O)2O-(alquilo C1-8), -(alquilo C1-8)m-SO2(arilo), -(alquilo C1-8)m-SO2(heteroarilo), -(alquilo C1-8)m-SO2(heterociclilo), -N(R9)(SO2-arilo), -N(R9)(SO2-heteroarilo), -N(R9)(SO2-heterociclilo), -N(R9)C(O)N(R9)(R9), -N(R9)C(O)N(R9)(arilo), -N(R9)C(O)N(R9)(heteroarilo), -N(R9)C(O)N(R9)(heterociclilo), -N(R9)C(O)C(O)N(R9)(R9), -N(R9)C(O)C(O)N(R9)(arilo), -N(R9)C(O)C(O)N(R9)(heteroarilo), -N(R9)C(O)C(O)N(R9)(heterociclilo), -N(R9)C(S)N(R9)(R9), -N(R9)C(S)N(R9)(arilo), -N(R9)C(S)N(R9)(heteroarilo), -N(R9)C(S)N(R9)(heterociclilo), -N(R9)SO2N(R9)(R9), -N(R9)SO2N(R9)(arilo), -N(R9)SO2N(R9)(heteroarilo), -N(R9)SO2N(R9)(heterociclilo), -S(alquilo C1-8), -SO2OH, NHC(NH)NH2, -N(R9)(arilo), -N(R9)(heteroarilo), -N(R9)(heterociclilo), -(alquilo C1-8)m-arilo, -(alquilo C1-8)m-heteroarilo, -(alquilo C1-8)m-heterociclilo, -oxo y -tioxo; R9 se selecciona entre hidrogeno o alquilo C1-8; donde, arilo presente como un sustituyente en R8 es un anillo monocíclico de cinco a siete miembros y heteroarilo y heterociclilo presentes como un sustituyente en R8 es un sistema de anillos monocíclicos de tres a siete miembros el cual contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno y azufre; donde el arilo, heteroarilo y heterociclilo están sin sustituir o sustituidos con uno a tres sustituyentes seleccionados independientemente entre el grupo formado por: oxo, tioxo, halogeno, -OH, -SH, -alquilo C1-8, -O(alquilo C1-8), nitro, amino, mono(alquil C1-8)amino, di(alquil C1-8)amino, -COOH, -CONH2, -CF3, -C(O)CF3, -SO2CF3, -S(alquilo C1-8), -SO2(alquilo C1-8) y -SO2NH2; donde, el dicho alquilo C1-8 antes mencionado es recto, ramificado o cíclico y puede contener un enlace doble y está sustituido con uno a dos sustituyentes seleccionados independientemente del grupo formado por: -OH, -SH, oxo, tioxo, amino, mono(alquil C1-3)amino, di(alquil C1-3)amino, -S(alquilo C1-3) y -alcoxi C1-3; donde alcoxi C1-3 es recto o ramificado, puede contener uno o dos enlaces dobles o triples; alquilo C1-3 es recto o ramificado; R9 se selecciona entre hidrogeno o alquilo C1-8; m es cero o uno; con la condicion de que cuando R1, se selecciona entre los siguientes no sustituidos o sustituidos a) ciclohexano, b) ciclohexeno o c) heteroarilo o heterociclilo monocíclico de seis miembros que tiene uno a dos heteroátomos seleccionados entre nitrogeno, oxígeno o azufre, entonces R8 como sustituyente en R1 no se selecciona entre el grupo hidroxilo y oxo; R2 se selecciona del grupo formado por: hidrogeno, halogeno, -alquilo C1-3, -OH, -SH, -O(alquiloC1-3), amino, mono(alquil C1-3)amino, di(alquil C1-3)amino, -C(O)CF3, -C(O)CH3, -SO2CF3, -CF3, -S(alquilo C1-8), -SO2(alquilo C1-8) y -SO2NH2; donde, el alquilo C1-8 antes mencionado es recto, ramificado o cíclico y puede contener uno o dos enlaces dobles o triples y está sustituido con uno a dos sustituyentes independientemente seleccionados del grupo formado por: -OH, -SH, oxo, tioxo, amino, mono(alquil C1-3)amino, di(alquil C1-3)amino, -S(alquilo C1-3) y -alcoxi C1-3; donde, alcoxi C1-3 es recto o ramificado, puede contener un enlace doble; alquilo C1-3 es recto o ramificado; R3 se selecciona entre el grupo formado por: halogeno, nitro, amino, -OH, -SH, -N(R9)C(O)(alquilo C1-8), -N(R9)C(O)(arilo), -N(R9)C(O)(heteroarilo), -N(R9)C(O)(heterociclilo), -N(R9)SO2(alquilo C1-8), -N(R9)SO2(arilo), -N(R9)SO2(heteroarilo), -N(R9)SO2(heterociclilo), -(alquilo C1-3), -(aIquilo C1-3)m-arilo, -(alquilo C1-3)m-heteroarilo, -(alquilo C1-3)m-heterociclilo, -C(O)N(R9)(R9), -C(O)N(R9)(arilo), -C(O)N(R9)(heteroarilo), -C(O)N(R9)(heterociclilo), -SO2N((R9)(R9), -SO2N((R9)(arilo), -SO2N((R9)(heteroarilo), -SO2N((R9)(heterociclilo), -N(R9)SO2CF3, -C(O)O-(aIquilo C1-8), -C(O)O-arilo, -C(O)O-heteroarilo, -C(O)O-heterociclilo, -N(R9)C(O)O-(alquilo C1-8), -N(R9)C(O)O-arilo, -N(R9)C(O)O-heteroarilo, -N(R9)C(O)O-heterociclilo, -CF3, -C(O)CF3, -SO2CF3, -COOH, -(alquil C1-3)m-O(alquilo C1-8), (aIquil C1-3)m-N((R9)(alquilo C1-8), -(alquil C1-3)-C(O)(alquilo C1-8), -(alquil C1-3)m-C(O)(arilo), -(alquil C1-3)m-C(O)(heteroarilo), -(alquil C1-3)m-C(O)(heterociclilo), C(O)(alquil C1-3)-arilo, C(O)(alquil C1-3)-heteroarilo, C(O)(alquil C1-3)-heterociclilo, -(alquil C1-3)-C(O)(alquil C1-3)-arilo, -(alquil C1-3)-C(O)(alquil C1-3)-heteroarilo, -(alquil C1-3)-C(O)(aIquil C1-3)-heterociclilo, -(aIquil C1-3)m-S(O)(alquilo C1-8), -(alquil C1-3)m-S(O)(arilo), -(alquil C1-3)m-S(O)(heteroarilo), -(aIquil C1-3)m-S(O)(heterociclilo), -(alquil C1-3)m-S(O)2-(alquilo C1-8), -(alquil C1-3)m-S(O)2-O-(alquilo C1-8), -(alquil C1-3)m-SO2(arilo), -(alquil C1-3)m-SO2(heteroarilo), -(alquil C1-3)m-SO2(heterociclilo), -S(O)2-(alquil C1-3)-arilo, -S(O)2(alquil C1-3)-heteroarilo, -S(O)2(alquil C1-3)-heterociclilo, -(alquil C1-3)SO2-(alquil C1-3)-arilo, -(alquil C1-3)SO2-(alquil C1-3)-heteroarilo, -(alquil C1-3)SO2-(alquil C1-3)-heterociclilo, -N(R9)SO2(arilo), -N(R9)SO2(heteroarilo), -N(R9)SO2(heterociclilo), -N(R9)C(O)N(R9)(R9), -N(R9)C(O)N(R9)(arilo), -N(R9)C(O)N(R9)(heteroarilo), -N(R9)C(O)N(R9)(heterociclilo), -N(R9)C(O)C(O)N(R9)(R9), -N(R9)C(O)C(O)N(R9)(arilo), -N(R9)C(O)C(O)N(R9)(heteroarilo), -N(R9)C(O)C(O)N(R9)(heterociclilo), -N(R9)C(S)N(R9)(R9), -N(R9)C(S)N(R9)(arilo), -N(R9)C(S)N(R9)(heteroarilo), -N(R9)C(S)N(R9)(heterociclilo), -N(R9)SO2N(R9)(R9), -N(R9)SO2N(R9)(arilo), -N(R9)SO2N(R9)(heteroarilo), -N(R9)SO2N(R9)(heterociclilo), -S(alquilo C1-8), -SO2OH, NHC(=NH)NH2, -(alquil C1-3)m-O(arilo), -(alquil C1-3)m-O(heteroarilo), -(alquil C1-3)m-O(heterociclilo), -(alquil C1-3)m-N(R9)(ariIo), -(alquil C1-3)m-N(R9)(heteroarilo), -(alquil C1-3)m-N(R9)(heterociclilo), -C(O)C(O)(arilo), -C(O)C(O)(heteroarilo), y -C(O)C(O)(heterociclilo); donde, dicho arilo presente como un sustituyente en R3 es un anillo monocíclico de cinco a siete miembros y heteroarilo y heterociclilo presentes como un sustituyente en R3 son un anillo monocíclico de tres a siete miembros el cual contiene uno o más heteroátomos seleccionados entre nitrogeno, oxígeno y azufre, donde dicho arilo, heteroarilo y heterociclilo están sin sustituir o sustituidos con uno a tres sustituyentes seleccionados independientemente entre el grupo formado por: oxo, tioxo, -OH, -SH, halogeno, -alquilo C1-8, -O(alquilo C1-8), nitro, amino, mono(alquil C1-8)amino, di(alquil C1-8)amino, -COOH, -CONH2, -CF3, -C(O)CF3, -SO2CF3, -S(alquilo C1-8), N(R9)SO2(alquilo C1-8), -SO2(alquilo C1-8), y -SO2NH2; donde, dicho alquilo C1-8 antes mencionado es recto, ramificado o cíclico y puede contener uno o dos enlaces dobles o triples y está con uno a dos sustituyentes seleccionados independientemente del grupo formado por: -OH, -SH, oxo, tioxo, amino, mono(alquil C1-3)amino, di(alquil C1-3)amino, -S(alquilo C1-3) y -alcoxi C1-3; donde alcoxi C1-3 es recto o ramificado, puede contener un enlace doble; alquilo C1-3 es recto o ramificado; m es cero o uno; R4 y R5 se selecciona independientemente en cada aparicion entre hidrogeno o R8 o ya sea R4o R5 junto con R7 es oxo; con la condicion de que cuando R4 es oxo, R3 no se selecciona entre -C(O)(alquilo C1-8), -C(O)O(alquiloC1-8), -C(O)(aIquilo C1-8)-arilo, -C(O)arilo, -C(O)tienilo, y -C(O)furilo; R6 se selecciona entre el grupo formado por: -(alquilo C1-8), -C(O)N(R9)(R9), -C(O)N(R9)(arilo), -C(O)N(R9)((alquil C1-8)-arilo), -C(O)N(R9)(heteroarilo), -C(O)N(R9)SO2(arilo), -C(O)N(R9)(heterociclilo), -C(S)N(R9)(R9), -C(S)N(R9)(arilo), -C(S)N(R9)(heteroarilo)
ARP080102806A 2007-06-29 2008-06-27 Piperidonas sustituidas como inductores hsp AR067357A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN947KO2007 2007-06-29

Publications (1)

Publication Number Publication Date
AR067357A1 true AR067357A1 (es) 2009-10-07

Family

ID=39764073

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102806A AR067357A1 (es) 2007-06-29 2008-06-27 Piperidonas sustituidas como inductores hsp

Country Status (13)

Country Link
US (1) US20100190824A1 (es)
EP (1) EP2178835A1 (es)
JP (1) JP2010531873A (es)
KR (1) KR20100027241A (es)
CN (1) CN101790516A (es)
AR (1) AR067357A1 (es)
AU (1) AU2008272437A1 (es)
BR (1) BRPI0812997A2 (es)
CA (1) CA2695031A1 (es)
MX (1) MX2009013775A (es)
RU (1) RU2010102899A (es)
TW (1) TW200904812A (es)
WO (1) WO2009004650A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594140A (en) 2008-12-22 2013-09-27 Chemocentryx Inc C5ar antagonists
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
CN103467227B (zh) * 2013-08-29 2015-04-29 中国科学院化学研究所 一种制备手性哌啶酮的方法
WO2015142903A2 (en) * 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
PT3200791T (pt) 2014-09-29 2020-05-06 Chemocentryx Inc Processos e intermediários na preparação de antagonistas c5ar
CA3010735C (en) 2016-01-14 2023-06-13 Chemocentryx, Inc. Use of n-benzoyl-2-phenyl-3-phenylcarbamoyl-piperidin derivative for treating complement 3 glomerulopathy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2399426A1 (fr) * 1977-08-04 1979-03-02 Unicler A-benzylidene-cycloalcanones et alcools correspondants et leur application en therapeutique
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
JPH06317878A (ja) * 1993-05-10 1994-11-15 Konica Corp ハロゲン化銀写真感光材料
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
CA2295055A1 (en) * 1997-06-27 1999-01-07 Kaneka Corporation Heat shock factor activity inhibitor
US6096711A (en) * 1998-02-25 2000-08-01 Sherman; Michael Hsp72 induction and applications
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6288235B1 (en) * 1999-04-14 2001-09-11 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
KR20070074638A (ko) * 2004-10-27 2007-07-12 얀센 파마슈티카 엔.브이. 테트라하이드로 피리디닐 피라졸 카나비노이드 모듈레이터

Also Published As

Publication number Publication date
JP2010531873A (ja) 2010-09-30
WO2009004650A1 (en) 2009-01-08
TW200904812A (en) 2009-02-01
US20100190824A1 (en) 2010-07-29
EP2178835A1 (en) 2010-04-28
AU2008272437A1 (en) 2009-01-08
BRPI0812997A2 (pt) 2014-12-23
RU2010102899A (ru) 2011-08-10
CA2695031A1 (en) 2009-01-08
KR20100027241A (ko) 2010-03-10
MX2009013775A (es) 2010-04-12
CN101790516A (zh) 2010-07-28

Similar Documents

Publication Publication Date Title
AR067357A1 (es) Piperidonas sustituidas como inductores hsp
AR070234A1 (es) Compuestos que comprenden un grupo ciclobutoxi
AR066459A1 (es) Derivados de oxadiazol como moduladores de gamma-secretasa. composiciones farmaceuticas
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR086319A1 (es) Compuestos heterociclicos fusionados como moduladores de canal ionico
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
AR063311A1 (es) Compuestos organicos
AR074275A1 (es) Derivados de oxoacetidina, procedimiento para su preparacion y su uso como moduladores de la melanocortina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR057034A1 (es) Metodos para purificar tigeciclina
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
AR075894A1 (es) Derivados oxidados de triazolilpurinas utiles como ligandos de receptor de adenosina a2a y su uso como medicamentos.
DOP2011000281A (es) Derivados de benzofurano
AR043674A1 (es) Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
AR054813A1 (es) Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas

Legal Events

Date Code Title Description
FB Suspension of granting procedure